天士力再登未来医疗100强 创新力榜单TOP100 创新战略驱动产业升级

Core Insights - Tianjin Tasly Pharmaceutical Group has been recognized in the "2025 Future Medical 100 Strong" list for its innovative capabilities in the healthcare sector, showcasing its role as a benchmark for traditional Chinese medicine innovation [1] Group 1: R&D Innovation - The company employs a "four-in-one" R&D model, with a pipeline of 98 products under development, including modern Chinese medicine, biological drugs, and chemical drugs for 2024 [3] - Key products in the innovation pipeline include three traditional Chinese medicine formulations in the production application stage and 17 products in clinical phases II and III [3] - In the biological drug sector, the product "Puyouke" has submitted a production application, with phase III clinical results published in the international journal "The Lancet Neurology" [3] Group 2: Intelligent Manufacturing - Tasly has established a modern intelligent manufacturing system recognized by the Ministry of Industry and Information Technology, ensuring quality traceability from raw material planting to finished product delivery [4] - The company has developed a high-speed pill-making machine that enhances drug loading and dissolution speed through electromagnetic suspension and cryogenic technology [4] Group 3: Market Innovation - The company has created a comprehensive product structure with modern Chinese medicine at its core, supported by high-quality chemical and biological drugs, covering various treatment areas [5] - Tasly has built a specialized promotion network across most regions of the country, ensuring coverage of grassroots medical institutions, with 14 products included in 20 guidelines and 16 clinical consensus applications in 2024 [5] - The company has received multiple awards for its digital marketing efforts, including the "Annual Digital Marketing Star" and "Social Public Welfare Award" for its innovative digital marketing platform [5]